Travere Therapeutics, Inc. TVTX Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s business segments — SG&A?
- Travere Therapeutics, Inc. (TVTX) reported business segments — SG&A of $80.25M in Q1 2026.
- How has Travere Therapeutics, Inc.'s business segments — SG&A changed year-over-year?
- Travere Therapeutics, Inc.'s business segments — SG&A increased by 32.8% year-over-year, from $60.41M to $80.25M.
- What is the long-term trend for Travere Therapeutics, Inc.'s business segments — SG&A?
- Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — SG&A has grown at a 18.0% compound annual growth rate (CAGR), from $197.52M to $324.78M.
- What does business segments — SG&A mean?
- This metric encompasses the costs of marketing, sales force operations, and general corporate overhead required to support the commercialization of products. It reflects the company's operational scale and the investment required to drive market penetration.